SCHEMBL16478282

SCHEMBL16478282

O=S(=O)(NCCN1CCC(CNCc2cc(Cl)sc2Cl)CC1)C1CC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 1/20 0.40
CXCR4 P61073 6/20 0.40
NPY5R Q15761 2/20 0.35
HTR1A P08908 2/20 0.35
DRD2 P14416 1/20 0.35
HTR7 P34969 1/20 0.35
HTR6 P50406 1/20 0.35
CACNA1I Q9P0X4 1/20 0.34
CYP2D6 P10635 2/20 0.34
CACNA1H O95180 1/20 0.34
KCNH2 Q12809 1/20 0.34
KMT2A Q03164 2/20 0.34
MEN1 O00255 1/20 0.34
ALDH1A1 P00352 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34
HTR4 Q13639 1/20 0.34
NPY1R P25929 1/20 0.34
PKM P14618 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4280004 0.83 CACNA1I (0.44) KDM1ACACNA1ICYP2D6CACNA1HKCNH2
SCHEMBL4275652 0.73 CACNA1I (0.67) CACNA1ICYP2D6CACNA1HKCNH2
SCHEMBL22019051 0.72 NPC1 (0.42) KDM1ACACNA1ICYP2D6CACNA1HKCNH2
SCHEMBL19112809 0.71 KDM1A (0.44) KDM1ANPY5RKCNH2ALDH1A1HTR4
SCHEMBL4274395 0.71 CACNA1I (0.58) CACNA1ICYP2D6CACNA1HKCNH2
SCHEMBL19113009 0.71 KCNH2 (0.41) KDM1ACACNA1ICYP2D6CACNA1HKCNH2
SCHEMBL1428801 0.70 KDM1A (0.46) KDM1ACACNA1ICYP2D6CACNA1HKCNH2
SCHEMBL4278285 0.70 CACNA1I (0.66) HTR7CACNA1ICYP2D6CACNA1HKCNH2
SCHEMBL4271000 0.69 CACNA1I (0.59) HTR7CACNA1ICYP2D6CACNA1HKCNH2
SCHEMBL4271496 0.69 KCNH2 (0.50) CACNA1ICYP2D6CACNA1HKCNH2HTR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140011996-A1 N-PIPERIDINYL ACETAMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS ZALICUS PHARMACEUTICALS LTD. (CA) 2014-01-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140011996-A1 N-PIPERIDINYL ACETAMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS CACNA1G, CACNA1H, CACNA1B KDM1A 3578/4885CXCR4 3881/4885NPY5R 3409/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.